Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:53:01 2024-06-11 pm EDT			5-day change	1st Jan Change
16.04 ^USD	+4.70%		-0.09%	+54.41%

12:00am	Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.	CI
12:00am	Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.	CI

Nurix Therapeutics, Inc. Reports Earnings Results for the Full Year Ended November 30, 2023

February 15, 2024 at 04:05 pm EST

Nurix Therapeutics, Inc. reported earnings results for the full year ended November 30, 2023. For the full year, the company reported revenue was USD 76.99 million compared to USD 38.63 million a year ago. Net loss was USD 143.95 million compared to USD 180.36 million a year ago.

Basic loss per share from continuing operations was USD 2.65 compared to USD 3.71 a year ago.

Latest news about Nurix Therapeutics, Inc.

Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.	2024-06-10	CI
Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.	2024-06-10	CI
Certain Pre-Funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.	2024-06-10	CI
Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.	2024-06-10	CI
Nurix Therapeutics, Inc. Appoints Paula G. O?Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer	May. 28	CI
Nurix Therapeutics Names New Board Chair	May. 20	MT
Nurix Therapeutics Announces Board Chair Transition	May. 20	CI
Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target	May. 14	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 12	MT
Sector Update: Health Care	Apr. 12	MT
North American Morning Briefing : Big Banks Kick off Earnings Season	Apr. 12	DJ
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share	Apr. 12	MT
Nurix Therapeutics Launching Public Offering -- Shares Fall After-Hours	Apr. 11	MT
Baird Adjusts Price Target on Nurix Therapeutics to $25 From $24, Maintains Outperform Rating	Apr. 11	MT
RBC Lifts Price Target on Nurix Therapeutics to $23 From $22, Keeps Outperform Rating, Speculative Risk Qualifier	Apr. 11	MT
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	Apr. 10	CI
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q1 Revenue $16.6M	Apr. 10	MT
North American Morning Briefing : Traders Await -2-	Apr. 10	DJ
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration	Apr. 09	DJ
Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	Apr. 09	CI
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate	Apr. 09	MT
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	Apr. 09	CI
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years	Apr. 02	MT
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration	Apr. 02	DJ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences	Apr. 02	CI

Chart Nurix Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

Sector

Biotechnology & Medical Research

Calendar

2024-06-16 - European Hematology Association Meeting - Abstract No: S155

More about the company

Income Statement Evolution

More financial data

Ratings for Nurix Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.32 USD

Average target price

24.67 USD

Spread / Average Target

+61.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NURIX THERAPEUTICS, INC.	+54.41%	909M
VERTEX PHARMACEUTICALS INCORPORATED	+18.16%	125B
REGENERON PHARMACEUTICALS, INC.	+14.80%	108B
BIONTECH SE	-6.67%	23.64B
ARGENX SE	+2.39%	22.39B
GENMAB A/S	-12.11%	17.78B
WUXI APPTEC CO., LTD.	-41.64%	16.43B
BEIGENE, LTD.	-13.96%	16.34B
NEUROCRINE BIOSCIENCES, INC.	+0.31%	13.56B
SAREPTA THERAPEUTICS, INC.	+24.74%	11.59B

Bio Therapeutic Drugs